Fecha de publicación: 08/09/2022 Fuente: WIPO "royal jelly" Use of a peptide or fragment thereof comprising SEQ ID NO. 1, or a peptide or fragment having at least 80% sequence identity thereto, in the manufacture of a medicament for one or more of reducing triglycerides, reducing LDL, reducing sdLDL, reducing glucose, reducing insulin, reducing HbA1c and increasing insulin sensitivity.